Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 59

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 59
---
 to actively monitor the bid price of our Common Stock and will consider available options to regain compliance with the Nasdaq listing requirements.

On May 27, 2025, we received written notice from Nasdaq stating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) because our stockholders’ equity of $1,439,404 as of March 31, 2025, as reported in our Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, was below the minimum requirement of $2,500,000 (the “Stockholders’ Equity Requirement”). As of the date of this prospectus, we do not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years, the alternative quantitative standards for continued listing on the Nasdaq Capital Market. The notification received has no immediate effect on our continued listing on the Nasdaq Capital Market, subject to our compliance with the other continued listing requirements, and our Common Stock will continue to trade on The Nasdaq Capital Market under the symbol “BIAF.”

Pursuant to Nasdaq’s Listing Rules, we have 45 calendar days (until July 11, 2025), to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1) (a “Compliance Plan”). We intend to submit a Compliance Plan within the required time, monitor our stockholders’ equity and, if appropriate, consider further available options to regain compliance with the Stockholders’ Equity Requirement, although there can be no assurance that the Compliance Plan will be accepted by Nasdaq. If the Compliance Plan is accepted by Nasdaq, we can be granted an extension of up to 180 calendar days from May 27, 2025 to regain compliance with the Stockholders’ Equity Requirement.

In the event the Compliance Plan is not accepted by Nasdaq, or in the event the Compliance Plan is accepted but we fail to regain compliance within the extension period, we will have the right to a hearing before Nasdaq’s Hearing Panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements, the stockholder’s equity requirement, or the minimum